Oral Vitamin D Supplementation in Elderly Women
1 other identifier
interventional
40
1 country
1
Brief Summary
The aim of this study is to compare oral vitamin D supplementation administered in two different ways, namely either twice a day (800IU/d, 292000IU/y) or three times a year (97333IU every 4 months, 292000IU/y) in elderly women in combination with daily supplementation of calcium 1 gram. We will 1)compare the blood concentrations of 25 OH vitamin D in the two treatment groups amd monitor if a sufficient and safe concentration of 25OH D in blood can be maintained with these two treatments.2) Find out seasonal variation in vitamin D concentrations in these treatments. 3) Find out safety of these treatments
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Oct 2006
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2006
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2007
CompletedFirst Submitted
Initial submission to the registry
December 17, 2007
CompletedFirst Posted
Study publicly available on registry
December 18, 2007
CompletedJanuary 8, 2008
December 1, 2007
December 17, 2007
December 26, 2007
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Blood 25 OH D vitamin concentrations
8 times during the year
Secondary Outcomes (1)
serum calcium, 24-hour calcium excretion in urine, creatinine clearance
8 times during the year
Study Arms (2)
1
ACTIVE COMPARATOR2
EXPERIMENTALInterventions
Vigantol oil , D3 20000IU/ml, 4.9 ml every four months for one year
Eligibility Criteria
You may qualify if:
- Females
- years
- Living in the community
You may not qualify if:
- Renal disease
- Diseases that contraindicate vitamin D supplementation
- Medications affecting bone
- Malignancy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Helsinkilead
- Päivikki and Sakari Sohlberg Foundation, Finlandcollaborator
- Lilly Foundationcollaborator
Study Sites (1)
Helsinki University Central Hospital, department of medicine, division of endocrinology
Helsinki, 00029 HUS, Finland
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
December 17, 2007
First Posted
December 18, 2007
Study Start
October 1, 2006
Study Completion
October 1, 2007
Last Updated
January 8, 2008
Record last verified: 2007-12